Pfizer Inc. (PFE) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription dru...
Pfizer Inc.'s revenue decreased 1.6% year over year, from $63.63B to $62.58B.
Net income decreased 3.2% over the same period, from $8.03B to $7.77B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 18% in total.
Total debt remained relatively stable at $65.15B.
The debt-to-equity ratio stands at 0.75, indicating a moderate leverage profile.
Operating cash flow declined 8.2% to $11.70B.
Pfizer Inc. maintains a healthy net profit margin of 12.4%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $44.25B+42.7% | $5.49B | $26.86B | $5.19B | $3.46B | $215.00B | $63.60B | $96.93B |
| Q1 FY2024 | $14.88B-66.4% | $3.12B | $11.50B | $3.42B | $1.09B | $221.00B | $69.54B | $92.28B |
| Q2 FY2024 | $28.16B+89.3% | $3.16B | $21.48B | $3.32B | $-691.0M | $216.00B | $69.45B | $87.70B |
| Q3 FY2024 | $45.86B+62.9% | $7.62B | $33.92B | $8.03B | $6.02B | $219.00B | $67.70B | $92.29B |
| Q1 FY2025 | $13.71B-70.1% | $2.97B | $10.87B | $2.79B | $2.33B | $208.00B | $62.11B | $90.34B |
| Q2 FY2025 | $28.37B+106.8% | $5.88B | $21.74B | $5.83B | $1.75B | $206.00B | $61.80B | $88.69B |
| Q3 FY2025 | $45.02B+58.7% | $9.42B | $34.23B | $9.16B | $6.36B | $209.00B | $61.71B | $92.80B |
| Q1 FY2026 | $14.45B-67.9% | $2.69B | $10.90B | $3.17B | $2.62B | $208.00B | $64.45B | $90.10B |
Balance Sheet Summary (Latest Period)
Total Assets
$208.00B
Total Liabilities
$121.39B
Total Equity
$86.48B
Cash & Equivalents
$13.60B
Total Debt
$65.15B
Current Assets
$42.90B
Current Liabilities
$36.98B
Retained Earnings
$114.61B